Clinical trials: II-IIIB Stages
Lung Cancer
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00754923
- Testing
- sorafenib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
This phase II trial studies how well anastrozole and letrozole after surgery work in treating patients with stage I-III breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04294225
- Testing
- Anastrozole, Letrozole
- Where
- 3 sites in United States
- Volunteers
- 161 people
- Sponsor
- Mayo Clinic
Breast Cancer
Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in higher doses over a shorter period of time may kill more tumor cells and have fewer side effects.
- Trial name
- NCT00872625
- Testing
- cyclophosphamide, docetaxel, epirubicin hydrochloride
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Centre Antoine Lacassagne
Breast Cancer
Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00754845
- Testing
- letrozole
- Where
- 43 sites in Canada, United Kingdom
- Volunteers
- 1,918 people
- Sponsor
- Canadian Cancer Trials Group
Melanoma
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab
The main goal of this research study is to determine how nivolumab and nivolumab/Vidutolimod (CMP-001) combination affect the likelihood of destroying melanoma involving lymph node and/or in-transit/satellite areas.
- Trial name
- NCT04401995
- Testing
- Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Diwakar Davar
Breast Cancer
Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab
RATIONALE: Monoclonal antibodies, such as trastuzumab and pertuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00301899
- Testing
- pertuzumab, trastuzumab
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
This phase I trial studies the side effects and best dose of SOR-C13 in treating patients with solid tumors that have spread to other places in the body (advanced) and does not respond to treatment.
- Conditions
- Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Ovarian Carcinoma, Refractory Pancreatic Carcinoma
- Trial name
- NCT03784677
- Testing
- TRPV6 Calcium Channel Inhibitor SOR-C13
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer
RATIONALE: Analyzing genes for changes before and after chemotherapy may help doctors predict a patient's response to treatment and help plan the most effective treatment.
- Trial name
- NCT00088829
- Testing
- paclitaxel, microarray analysis, biopsy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Georgetown University
Lung Cancer
Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00003881
- Testing
- trastuzumab, carboplatin, paclitaxel
- Where
- 71 sites in United States, Puerto Rico and 1 more
- Sponsor
- Eastern Cooperative Oncology Group
IMMUNOTHERAPY, Neoadjuvant Therapy
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
This study aims to evaluate the efficacy and safety of neoadjuvant camrelizumab combined with chemotherapy in resectable stage IIIA and IIIB (T3-4N2) non-small cell lung cancer (NSCLC) patients.
- Conditions
- IMMUNOTHERAPY, Neoadjuvant Therapy, Resectable Lung Non-Small Cell Carcinoma, Biomarkers / Blood
- Trial name
- NCT06241807
- Testing
- Camrelizumab Plus Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shandong Cancer Hospital and Institute
Breast Cancer
Studying Tumor Samples From Women Who Have Undergone Chemotherapy for Breast Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897845
- Testing
- RNA analysis, microarray analysis, immunohistochemistry staining method
- Volunteers
- 2,541 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Cancer
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00004900
- Testing
- filgrastim, anastrozole, carboplatin
- Where
- United States
- Sponsor
- Hackensack Meridian Health
Non Small Cell Lung Cancer, Adenocarcinoma
Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers
Intercalated administration of Iressa® (gefitinib) on days 5-18 of chemotherapy cycle improve the efficacy of Pemetrexed/platinum regimen given as first-line treatment for never-smokers with advanced (stage IIIB/IV) lung…
- Trial name
- NCT01502202
- Testing
- Gefitinib, Pemetrexed plusCIsplatin
- Where
- South Korea
- Volunteers
- 162 people
- Sponsor
- National Cancer Center, Korea
Lung Cancer, Non Small Cell Lung Carcinoma
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
This open-label, multicenter, randomized, controlled, Phase II study is planned to answer questions about how the drug, matuzumab (EMD 72000), works and is part of an effort aimed to develop better treatment for advanced lung…
- Trial name
- NCT00111839
- Testing
- Pemetrexed, Matuzumab
- Where
- 58 sites in United States, Austria and 1 more
- Volunteers
- 150 people
- Sponsor
- EMD Serono
Cervical Large Cell Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma
Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix
This study collects information and data on patients with neuroendocrine cervical cancer. Information from this study may be used to better understand the correlation between clinical data, such as patient characteristics…
- Conditions
- Cervical Large Cell Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Cervical Small Cell Carcinoma, Cervical Undifferentiated Carcinoma
- Trial name
- NeCTuR (NCT04723095)
- Testing
- Follow-Up, Medical Chart Review
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer
Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003732
- Testing
- carboplatin, paclitaxel, topotecan hydrochloride
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
HER2-positive Breast Cancer, Male Breast Cancer
Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
This randomized phase I/II trial studies the side effects and best dose of rintatolimod when given together with vaccine therapy and sargramostim (GM-CSF) to see how well it works in treating patients with stage II-IV human…
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01355393
- Testing
- HER-2/neu peptide vaccine, sargramostim, rintatolimod
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Lung Cancer
Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00182806
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer
Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women
RATIONALE: Studying mammograms for breast density changes over time may help doctors predict breast cancer risk. PURPOSE: This natural history study is looking at changes in breast density and gathering health information over…
- Trial name
- NCT00445445
- Testing
- physiologic testing, screening questionnaire administration, breast imaging study
- Where
- 8 sites in United States
- Volunteers
- 2,201 people, healthy volunteers welcome
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer, Lymphoma
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Filgrastim and stem cell factor may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's…
- Trial name
- NCT00005993
- Testing
- aldesleukin, filgrastim, recombinant human stem cell factor
- Sponsor
- Masonic Cancer Center, University of Minnesota
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.